DIFICID 200 MG — DIN 02387174
FIDAXOMICIN : 200 MG · MERCK CANADA INC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is DIFICID?
DIFICID 200 MG contains FIDAXOMICIN : 200 MG. It is listed in the Health Canada Drug Product Database under DIN 02387174, held by MERCK CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 20-Sep-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DIFICID used for?
DIFICID® (fidaxomicin) is indicated in adults (≥18 years of age) for the treatment of Clostridium difficile infection (CDI). To reduce the development of drug-resistant bacteria and maintain the effectiveness of DIFICID® and other antibacterial drugs, DIFICID® should be used only to treat infections that are proven or strongly suspected to be caused by Clostridium difficile.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Fidaxomicin cost around the world?
Fidaxomicin is listed on 9 of the national price registers Nexara ingests. Each country publishes on a different basis, so figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Austria publishes a KVP (Kassenverkaufspreis); Greece publishes a producer price (ex-factory); Hungary publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed |
|---|---|---|---|
| United States | acquisition | 1 | 3 |
| Austria | KVP (Kassenverkaufspreis) | 1 | 1 |
| Greece | producer price (ex-factory) | 1 | 1 |
| Hungary | producer price (ex-factory) | 1 | 1 |
| Iceland | max wholesale | 1 | 1 |
| Luxembourg | reimbursement | 1 | 1 |
| Romania | max producer price | 1 | 1 |
| Saudi Arabia | public | 1 | 1 |
| South Africa | single exit price | 1 | 1 |
11 pack listings across 9 brand entries and 8 price bases, refreshed 05 Sep 2026. Ranges span every Fidaxomicin pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 200 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | 30 cc HDPE bottles capped with induction seal closure; 20 film-coated tablets per bottle. 60 cc HDPE bottles capped with induction seal closure; 60 film-coated tablets per bottle. 20 × 1 alu/alu perforated unit dose blisters (10 film-coated tablets per card; 2 cards per carton). 100 × 1 alu/alu perforated unit dose blisters (10 film-coated tablets per card; 10 cards per carton). |
| Storage | Store between 15°C and 30°C. Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date. Store in a tightly closed container away from heat and direct light. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Fidaxomicin |
|---|---|
| ATC code | A07AA12 |
| AHFS class | 08:12.12.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02387174 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2387174 |
| Brand name | DIFICID |
| Generic / active ingredient | FIDAXOMICIN : 200 MG |
| Market authorization holder | MERCK CANADA INC |
| Health Canada schedule | Prescription |
| ATC code | A07AA12 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A07AA |
| Current status | MARKETED |
| Status date | 20-Sep-2016 |
| Original market date | 2012-06-21 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
The recommended dose for adults ≥18 years of age is one 200-mg DIFICID® tablet orally twice daily for 10 days with or without food. If a dose is missed, it should be taken as soon as possible. However, if it is almost time for the next dose, no additional dose should be taken and the regular dosing schedule should be resumed. No more than two doses of DIFICID® (1 tablet twice a day) should be taken in a 24-hour period. No dose adjustment in adults is necessary based on age or gender, renal function or hepatic impairment.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to this drug or to any ingredient in the formulation or component of the container.
Warnings and precautions
Not for Systemic Infections: Since there is minimal systemic absorption of fidaxomicin, DIFICID® should not be used for the treatment of systemic infections. Development of Drug Resistant Bacteria: Prescribing DIFICID® in the absence of a proven or strongly suspected C. difficile infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. Hypersensitivity: Acute hypersensitivity reactions, such as dyspnea, rash, pruritus, and angioedema of the mouth, throat, and face have been reported with fidaxomicin. If a severe hypersensitivity reaction occurs, DIFICID® should be discontinued and appropriate therapy should be instituted. Some patients with hypersensitivity reactions also reported a history of allergy to macrolides. Physicians prescribing DIFICID® to patients with a known macrolide allergy should be aware of the possibility of hypersensitivity reactions.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
2 · Same class — other molecules in ATC A07AA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Vancomycin | JAMP VANCOMYCIN · PMS-VANCOMYCIN · PMSC-VANCOMYCIN · VANCOCIN | 8 | 4 | Yes |
| Nystatin | DOM-NYSTATIN SUSPENSION · FTP-NYSTATIN · JAMP-NYSTATIN ORAL SUSPENSION USP · MYCOSTATIN ORAL SUSPENSION 100000IU · +11 more | 15 | 3 | Yes |
| Fidaxomicin | DIFICID | 1 | 1 | Yes |
| Paromomycin | HUMATIN | 1 | 1 | Yes |
| Rifaximin | ZAXINE | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is DIFICID called?
Also recorded in Canada as: fidaxomicin 200 MG Oral Tablet [Dificid] (US), fidaxomicin 40 MG/ML Oral Suspension [Dificid] (US), fidaxomicin 200 MG Oral Tablet (US), fidaxomicin 40 MG/ML Oral Suspension (US), FIDAXOMICIN (US), DIFICLIR (EU), DIFICLIR (UK), DIFICLIR (JP), DIFICLIR (KR), FIDAXOMICIN (GLOBAL), FIDAXOMICIN (UK), OPT-80 (GLOBAL), PAR-101 (GLOBAL).
The same molecule, Fidaxomicin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Dificlir | Latin | Iceland |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.